The Hopkins Lupus Pregnancy Center: Ten Key Issues in Management

Rheumatic Disease Clinics of North America

Volumn 33, Issue 2, 2007, Pages 227-235

  Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCIUM; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GESTAGEN; HYDRALAZINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METHYLDOPA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; PROGESTERONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; COGNITIVE DEFECT; CONTRACEPTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE EXACERBATION; ENDOMETRIOSIS; ENVIRONMENTAL EXPOSURE; FETUS DEATH; FETUS MALFORMATION; FETUS WASTAGE; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GROWTH INHIBITION; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INTRAUTERINE CONTRACEPTIVE DEVICE; LABORATORY TEST; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROLOGIST; NEWBORN DISEASE; NONHUMAN; OBSTETRIC CARE; OVARY CYST; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; REVIEW; RHEUMATOLOGY; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH;

EID: 34248154135     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.01.003     Document Type: Review

References (26)

1. Sanchez-Guerrero J., Karlson E.W., Liang M.H., et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 40 (1997) 804-808
2. Jungers P., Dougados M., Pelissier C., et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 618-623
3. Petri M., and Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 40 (1997) 797-803
4. Agarwal S., Waltrous J., and Petri M. Gynecological problems are more common in SLE than in the general female population. [abstract]. Arthritis Rheum 54 9 Suppl (2006) S445
5. Arden N.K., Nevitt M.C., Lane N.E., et al. Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 42 7 (1999) 1378-1385
6. Keisler L.W., Kier A.B., and Walker S.E. Effects of prolonged administration of the 19-nor-testosterone derivatives norethindrone and norgestrel to female NZB/W mice: comparison with medroxyprogesterone and ethinyl estradiol. Autoimmunity 9 1 (1991) 21-32
7. Sullivan K.E. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 26 2 (2000) 229-256 v-vi
8. Harley J.B., and James J.A. Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers. [letter]. Arthritis Rheum 42 8 (1999) 1782-1783
9. Costenbader K.H., Kim D.J., Peerzada J., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 50 3 (2004) 849-857
10. Roubenoff R., Hoyt M., Petri M., et al. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 18 (1988) 88-110
11. Ostensen M., Khamashta M., Lockshin M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8 3 (2006) 209
12. Yeh T.F., Lin Y.J., Lin H.C., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350 13 (2004) 1304-1313
13. Ofori B., Oraichi D., Blais L., et al. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Defects Res B Dev Reprod Toxicol 77 4 (2006) 268-279
14. Parke A., and West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23 (1996) 1715-1718
15. Parke A.L. Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 15 (1988) 607-610
16. Clowse M., Magder L., Witter F., et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54 (2006) 3640-3647
17. Le Ray C., Coulomb A., Elefant E., et al. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 5 Pt 2 (2004) 1091-1094
18. Clowse M.E., Magder L., and Petri M. Cyclophosphamide for lupus during pregnancy. Lupus 14 8 (2005) 593-597
19. Clowse M.E., Magder L.S., Witter F., et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52 2 (2005) 514-521
20. Doria A., Ghirardello A., Iaccarino L., et al. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum 51 6 (2004) 989-995
21. Petri M., Howard D., and Repke J. Frequency of lupus flare in pregnancy: The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 34 (1991) 1538-1545
22. Ruiz-Irastorza G., Lima F., Alves J., et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 35 2 (1996) 133-138
23. Lockshin M.D., Reinitz E., Druzin M.L., et al. Lupus pregnancy. I. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 77 (1984) 893-898
24. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354 23 (2006) 2443-2451
25. Holers V.M., Girardi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195 2 (2002) 211-220
26. Branch D.W., Peaceman A.M., Druzin M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 182 1 Pt 1 (2000) 122-127